Search for a command to run...
SaferSkin 2.0 is the latest version of our in silico application for skin sensitization, offering a software for comparing and reporting the results of models and defined approaches for skin sensitization. This innovative tool supports risk assessment and regulatory compliance. SaferSkin is an open-source computational platform designed to support integrated assessment of skin sensitisation hazards using multiple predictive models, mechanistic New Approach Methodologies (NAMs), and probabilistic evidence integration. The platform enables structured comparison of predictions across modelling tools and facilitates transparent weight-of-evidence interpretation aligned with modern Next Generation Risk Assessment (NGRA) frameworks. Skin sensitisation is an immune-mediated adverse outcome resulting from repeated exposure to reactive chemicals and is a major endpoint in regulatory toxicology and consumer product safety. Traditional hazard identification has relied on animal testing methods such as the Local Lymph Node Assay (LLNA). Increasing regulatory and ethical pressures have led to the development of alternative approaches including computational toxicology models and mechanistic in chemico and in vitro assays aligned with the Adverse Outcome Pathway (AOP) for skin sensitisation. Despite these advances, individual predictive models frequently produce inconsistent results due to differences in training datasets, mechanistic coverage, and applicability domains. SaferSkin addresses this challenge by providing an integrated environment for consensus modelling, model comparison, and probabilistic evidence integration.